Sort   by:  
 Page size 
MetabolomicsThe efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that induce selective protein degradation by linking an E3 ubiquitin ligase enzyme to a target protein. This approach allows scope for targeting “undruggable” proteins and several PROTACs have reached the stage of clinical candidate...
2025-07-17 | MTBLS11394 | MetaboLights
MetabolomicsMetabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei
In vitro culture methods underpin many experimental approaches to biology and drug discovery. The modification of established cell culture methods to be more biologically relevant, or to optimise growth, is traditionally a laborious task. Emerging metabolomics technology enables rapid evaluation of ...
2015-05-14 | MTBLS49 | MetaboLights
MetabolomicsComprehensive High-Resolution Multiple-Reaction Monitoring Mass Spectrometry for Targeted Eicosanoid Assays
Eicosanoids comprise a class of bioactive lipids derived from a unique group of essential fatty acids that mediate a variety of important physiological functions. Owing to the structural diversity of these lipids, their analysis in biological samples is often a major challenge. Advancements in mass ...
2018-06-26 | MTBLS641 | MetaboLights
TranscriptomicsGenetic and molecular basis of drug resistance and species-specific drug action in Schistosome parasites
Oxamniquine resistance evolved in the human blood fluke (Schistosoma mansoni) in Brazil in the 1970s. We crossed parental parasites differing ~500-fold in drug response, determined drug sensitivity and marker segregation in clonally-derived F2s, and identified a single QTL (LOD=31) on chromosome 6. ...
ORGANISM(S): Schistosoma mansoni 
2013-12-05 | E-GEOD-51847 | biostudies-arrayexpress
TranscriptomicsGenome-wide DNA copy number predictors of lapatinib sensitivity in tumour-derived cell lines
A common aim of pharmacogenomic studies that employ genome-wide assays on panels of cancers is the unbiased discovery of genomic alterations that are associated with clinical outcome and drug response. Previous investigations of lapatinib, a selective dual-kinase inhibitor of EGFR and HER2 tyrosine...
ORGANISM(S): Homo sapiens 
2008-03-10 | E-GEOD-9585 | biostudies-arrayexpress
MetabolomicsMetabolic characterization of the natural progression of chronic hepatitis B (Biogenic amine and Acyl-carnitine assays)
Background: Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, e...
2016-06-06 | MTBLS280 | MetaboLights
MetabolomicsCalenduloside E produced by Bifidobacterium animalis B960 increases glibenclamide efficacy and alleviates drug-induced adverse effects via the IRS1/PI3K/AKT signaling pathway in a type 2 diabetes model Calenduloside E produced by Bifidobacterium animalis B960 increases glibenclamide efficacy and alleviates drug-induced adverse effects via the IRS1/PI3K/AKT signaling pathway in cell, organ-on-a-chip, and mouse models of type 2 diabetes.

Glibenclamide (GLIB), a type 2 diabetes therapy, has long-term safety concerns. Probiotic–drug coadministration, an emerging adjunctive approach for metabolic diseases, improves therapeutic outcomes and side effects. Here, Bifidobacterium animalis B960 was selected from 71 probiotic strains by HP...

2025-07-08 | MTBLS12697 | MetaboLights
ProteomicsProteomic-based identification of APCS as candidate protein for diagnosis of patients exhibiting Anti-tubercular drug induced liver injury
In the present study, the proteomics approach identified potential protein signatures with high discriminative ability in TB patients with and without drug-induced liver injury which might play a crucial role in developing Anti-tubercular drug-induced liver injury.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2021-11-12 | MSV000088373 | MassIVE
MetabolomicsCharacterisation of monophasic solvent-based tissue extractions for detection of polar metabolites and lipids applying UHPLC-MS clinical metabolic phenotyping assays

Metabolic phenotyping of tissues uses metabolomics and lipidomics to measure the relative polar and non-polar (lipid) metabolite levels in biological samples. This approach aims to understand disease biochemistry and identify biochemical markers of disease. Sample preparation methods must be repr...

2020-09-28 | MTBLS1707 | MetaboLights
UnknownStandardized assays to monitor drug sensitivity in hematologic cancers.
Not available
S-EPMC10692209 | biostudies-literature
Sort   by:  
 Page size